Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now

FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.

Zacks Investment Research • Dec 11, 2025

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Germany , Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026.

PRNewsWire • Dec 10, 2025

Here's Why Fresenius (FMS) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 26, 2025

Fresenius Medical Care: 'Buy' Again Following A Peak In May

Fresenius Medical Care (FMS) is rated a 'Buy,' citing strong fundamentals. FMS demonstrates robust revenue growth, margin expansion, and dividend safety, with a new HVHDF product rollout expected to drive future upside. Despite market concerns over GLP-1 drugs and recent share declines, FMS is positioned for double-digit EPS growth and offers a well-covered 3-4% yield.

Seeking Alpha • Nov 25, 2025

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Nov 10, 2025

FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y

Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.

Zacks Investment Research • Nov 5, 2025

Fresenius Medical Care beats quarterly profit estimates helped by cost cuts

Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take hold.

Reuters • Nov 4, 2025

Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Transcript

Fresenius Medical Care AG ( FMS ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Call Participants Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Veronika Dubajova - Citigroup Inc., Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Hugo Solvet - BNP Paribas, Research Division Graham Doyle - UBS Investment Bank, Research Division David Adlington - JPMorgan Chase & Co, Research Division Anna Ractliffe - BofA Securities, Research Division Presentation Operator Ladies and gentlemen, welcome to the report on the Third Quarter 2025 Conference Call. I am Sandra, the Chorus Call operator.

Seeking Alpha • Nov 4, 2025

Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7% Reported operating income grew by 3%, reported net income3 by 29% Net leverage ratio further improved to 2.6x, in parallel to share buyback and Value-Based Care investments FY 2025 outlook confirmed BAD HOMBURG, Germany, Nov. 4, 2025 /PRNewswire/ -- "In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress.

PRNewsWire • Nov 4, 2025

Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025

Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation highlights the association between HDF and reduced risk of cardiovascular and fluid-related hospitalization outcomes.

PRNewsWire • Oct 30, 2025